Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Alpelisib

Drug and asset intelligence for Alpelisib with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 1
Stage: Development stage unavailable

Sponsor company

Mechanism of action

PI3K Inhibitor

Recent signals(2)

ClinicalAugust 2, 2026

Phase II Study of Alpelisib in PIK3CA-related Overgrowth Spectrum Initiated

A Phase II single-arm study is underway to evaluate the efficacy and safety of alpelisib in patients with PROS.

ClinicalJuly 10, 2026

Novartis initiates study on Alpelisib and Fulvestrant for advanced HR+ breast cancer

Novartis is conducting a study to evaluate the efficacy and safety of alpelisib plus fulvestrant in HR-positive, HER2-negative advanced breast cancer patients who have progressed after prior treatments.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(1)

Topline Data

Novartis — Alpelisib

July 10, 2026 · N/A

Indications

Breast Cancer →

Therapeutic areas

Breast Cancer →

Oncology · Breast Cancer →

Oncology · PI3K Inhibitor →

PI3K Inhibitor →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.